Pharmicell announced on May 8 that it achieved its highest-ever quarterly results in the first quarter of this year, recording sales of 27 billion KRW and an operating profit of 8.4 billion KRW. Compared to the same period last year, sales increased 2.5 times, and the company turned to an operating profit. This is a remarkable improvement compared to the first quarter of last year, when sales were 11 billion KRW and there was an operating loss of 2 billion KRW.
The quarterly operating profit surpassed the annual operating profit of 4.7 billion KRW recorded in 2024, continuing the company's steep growth trajectory.
The Biochemical Division accounted for most of the sales, generating 26.4 billion KRW. Driven by the growth of the artificial intelligence (AI) industry, low-dielectric electronic materials sales reached 16.6 billion KRW, making up 62% of total sales and leading the company's performance. Active pharmaceutical ingredient sales also reached 4.3 billion KRW, establishing themselves as a major source of revenue.
Sales of low-dielectric electronic materials increased by 386% year-on-year, from 3.4 billion KRW to 16.6 billion KRW, while active pharmaceutical ingredient sales rose by 124% to 4.3 billion KRW. Overall, the Biochemical Division's sales grew by 149% year-on-year to 26.4 billion KRW.
A Pharmicell representative stated, "The strong performance is due to low-dielectric electronic materials becoming a core material as the AI market rapidly expands," adding, "Pharmicell's outstanding technological capabilities and stable product supply capacity played a crucial role."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
